Home / Psoriasis / OWCP and mediq Collaborate to Introduce Cannabinoid-based Psoriasis Cream

OWCP and mediq Collaborate to Introduce Cannabinoid-based Psoriasis Cream

One World Cannabis Pharmaceutical Research (OWCP) and mediq Innovation Experts have partnered to introduce OWCP’s cannabinoid-based topical psoriasis cream in Germany.

Germany-based mediq has extensive experience in assisting companies based in Israel enter European markets. Under the new agreement, mediq will support OWCP with both a scientific collaboration and in marketing its active cannabinoid-based topical psoriasis cream in Germany.

OWCP recently reported the initial results from a clinical trial evaluating the cannabinoid-based topical cream for the treatment of psoriasis. According to the results, the cream led to a 70 percent improvement in psoriasis-related inflammation parameters. Based on the promising study data, the company said it will expand the size and scope of its clinical trial.

In April, the company said it will provide more details of the study upon availability of final data, and completion of what it calls the full “Bio-Data IP Protection.”

Full Article

About Dr. J. Kim

Dr Kim developed (and is continuing to develop) dermatology research news as we way from dermatologists to stay on top of the latest advances in the field of dermatology.

Check Also

A Study to Evaluate BMS-986165 Tablet Formulation Relative to BMS-986165 Capsule Formulation and the Effect of a High-Fat/ High-Calorie Meal and Increased Gastric pH on the BMS-986165 Tablet Formulation

  Purpose The purpose of this study is to evaluate BMS-986165 tablet formulation versus BMS-986165 …

Leave a Reply

Your email address will not be published. Required fields are marked *